GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Toleranzia AB (OSTO:TOL) » Definitions » EV-to-EBITDA

Toleranzia AB (OSTO:TOL) EV-to-EBITDA : -12.07 (As of May. 12, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Toleranzia AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Toleranzia AB's enterprise value is kr88.57 Mil. Toleranzia AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was kr-7.34 Mil. Therefore, Toleranzia AB's EV-to-EBITDA for today is -12.07.

The historical rank and industry rank for Toleranzia AB's EV-to-EBITDA or its related term are showing as below:

OSTO:TOL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.8   Med: -1.07   Max: 4.32
Current: -12.07

During the past 10 years, the highest EV-to-EBITDA of Toleranzia AB was 4.32. The lowest was -57.80. And the median was -1.07.

OSTO:TOL's EV-to-EBITDA is ranked worse than
100% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.76 vs OSTO:TOL: -12.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Toleranzia AB's stock price is kr0.538. Toleranzia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.060. Therefore, Toleranzia AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Toleranzia AB EV-to-EBITDA Historical Data

The historical data trend for Toleranzia AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Toleranzia AB EV-to-EBITDA Chart

Toleranzia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.49 -8.32 -8.83 -10.75 -9.11

Toleranzia AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.75 -10.15 -10.84 -9.62 -9.11

Competitive Comparison of Toleranzia AB's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Toleranzia AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Toleranzia AB's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Toleranzia AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Toleranzia AB's EV-to-EBITDA falls into.



Toleranzia AB EV-to-EBITDA Calculation

Toleranzia AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=88.570/-7.341
=-12.07

Toleranzia AB's current Enterprise Value is kr88.57 Mil.
Toleranzia AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-7.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Toleranzia AB  (OSTO:TOL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Toleranzia AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.538/-0.060
=At Loss

Toleranzia AB's share price for today is kr0.538.
Toleranzia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.060.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Toleranzia AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Toleranzia AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Toleranzia AB (OSTO:TOL) Business Description

Traded in Other Exchanges
N/A
Address
Erik Dahlbergsgatan 11A, Gothenburg, SWE, SE-411 26
Toleranzia AB is a pharmaceutical company based in Sweden. The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an orphan disease.